Sanofi/$SNY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Ticker
$SNY
Sector
Primary listing
Employees
82,878
Headquarters
Website
Sanofi Metrics
BasicAdvanced
$120B
5.81
$8.55
0.44
$1.60
3.22%
Price and volume
Market cap
$120B
Beta
0.44
52-week high
$60.12
52-week low
$44.62
Average daily volume
3M
Dividend rate
$1.60
Financial strength
Current ratio
1.06
Quick ratio
0.293
Long term debt to equity
18.041
Total debt to equity
29.585
Dividend payout ratio (TTM)
51.62%
Interest coverage (TTM)
24.55%
Profitability
EBITDA (TTM)
14,264.148
Gross margin (TTM)
72.00%
Net profit margin (TTM)
19.84%
Operating margin (TTM)
20.90%
Effective tax rate (TTM)
19.14%
Revenue per employee (TTM)
$636,060
Management effectiveness
Return on equity (TTM)
8.84%
Valuation
Price to earnings (TTM)
5.81
Price to revenue (TTM)
1.151
Price to book
1.42
Price to tangible book (TTM)
23.67
Price to free cash flow (TTM)
6.672
Free cash flow yield (TTM)
14.99%
Free cash flow per share (TTM)
7.443
Dividend yield (TTM)
3.22%
Forward dividend yield
3.22%
Growth
Revenue change (TTM)
-5.19%
Earnings per share change (TTM)
105.93%
3-year revenue growth (CAGR)
1.18%
10-year revenue growth (CAGR)
2.13%
3-year earnings per share growth (CAGR)
13.17%
10-year earnings per share growth (CAGR)
6.34%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Dupixent sales reached €4.16 billion in Q3 2025, beating consensus expectations of €4 billion and affirming its role as a major growth contributor.
On July 31, 2025, Sanofi raised its full-year sales growth forecast to high single digits thanks to a 21.1% y/y increase in Q2 Dupixent sales to €3.83 billion, demonstrating continued solid demand.
Sanofi’s $1.15 billion acquisition of UK-based Vicebio strengthens its vaccines pipeline with new RSV and hMPV candidates, expanding its presence in respiratory vaccines and diversifying its portfolio.
Q3 2025 vaccine sales fell 16.8% due to pricing pressures and weaker vaccination rates, highlighting risk in Sanofi’s vaccines segment and reducing revenue diversification.
The Phase III trial for amlitelimab, intended as a follow-up to Dupixent, failed to meet investor expectations for efficacy—even though endpoints were met—which drove shares down more than 9% and raised doubts about the strength of Sanofi’s pipeline beyond Dupixent.
Dupixent makes up nearly 40% of Sanofi’s total revenue and faces patent expiry in 2031, increasing the risk of a substantial revenue decline as early-stage pipeline candidates have shown disappointing results.
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Sanofi News
AllArticlesVideos
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
WSJ2 weeks ago
Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged
Reuters2 weeks ago
QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SNY) has a market cap of $120B as of November 08, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SNY) stock is 5.81 as of November 08, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SNY) stock pays dividends to shareholders. As of November 08, 2025, the dividend rate is $1.59864 and the yield is 3.22%. Sanofi has a payout ratio of 51.62% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SNY) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SNY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.